2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(allyloxy)phenyl)propanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(4-(allyloxy)phenyl)propanoic acid
• 英文别名: 2-{[(9H-fluoren-9-ylmethoxy)carbonyl]amino}-3-[4-(prop-2-en-1-yloxy)phenyl]propanoic acid；2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-(4-prop-2-enoxyphenyl)propanoic acid
• 化学式: C₂₇H₂₅NO₅
• 分子量: 443.499
• InChiKey: AQUXDQFCBLRIRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS
  申请人：Ensemble Therapeutics Corp.

  公开号：US20140135270A1

  公开（公告）日：2014-05-15

  There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

  这里公开了调节凋亡抑制剂（IAPs）活性的化合物，包含所述化合物的药物组合物以及使用本发明的化合物治疗增殖性疾病和凋亡失调疾病的方法，例如癌症。
• MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa
  申请人：Kallus Christopher

  公开号：US20110178130A1

  公开（公告）日：2011-07-21

  The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

  该发明涉及式(I)的化合物，这些化合物是激活的凝血酶可激活的纤溶抑制剂的抑制剂。式I的化合物适用于生产用于预防、次级预防和治疗与血栓形成、栓塞、高凝血性或纤维化变化相关的一个或多个疾病的药物。
• [EN] IMMUNOMODULATORS<br/>[FR] IMMUNOMODULATEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019070643A1

  公开（公告）日：2019-04-11

  The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.

  本公开提供了一种新型的大环肽，其能够抑制PD-1/PD-L1和PD-L1/CD80蛋白质/蛋白质相互作用，因此可用于改善各种疾病，包括癌症和传染病。
• MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA
  申请人：Kallus Christopher

  公开号：US20140039011A1

  公开（公告）日：2014-02-06

  The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

  本发明涉及公式（I）的化合物，它们是活化的凝血酶-可激活纤溶抑制剂的抑制剂。公式I的化合物适用于生产预防、次级预防和治疗与血栓、栓塞、高凝状态或纤维化变化相关的一个或多个疾病的药物。
• IMMUNOMODULATORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP3692053A1

  公开（公告）日：2020-08-12